Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

Cyfuse Biomedical FY ending Dec 2023 results

Cyfuse Biomedical brought in ¥61.1M in revenue.

It lost about ¥1141 for every ¥100 of sales at the operating level.

Revenue changed -83.7% from the prior year.

What changed from last year

FY ending Dec 2022 → FY ending Dec 2023

Revenue
-83.7%¥374.5M → ¥61.1M
Gross profit
-84.4%¥241.5M → ¥37.7M
Operating income
Loss-¥425.1M → -¥697.4M
Operating cash flow
Loss-¥403.6M → -¥562.3M
Free cash flow
Loss-¥631.9M → -¥581.8M

Where the money goes

FY ending Dec 2022 → FY ending Dec 2023

Where ¥100 of sales goes

For every ¥100 Cyfuse Biomedical sells, how much goes where, and how much is kept.

FY ending Dec 2023
Cost of sales
¥38
SG&A
¥1203
Operating loss
¥1141
Net loss
¥964

Annual margin trends

Gross margin61.8%
FY ending Dec 2021: 80.6%80.6%FY ending Dec 2022: 64.5%64.5%FY ending Dec 2023: 61.8%61.8%FY21FY22FY23
Operating margin-1141.2%
FY ending Dec 2021: 10.0%10.0%FY ending Dec 2022: -113.5%-113.5%FY ending Dec 2023: -1141.2%-1141.2%FY21FY22FY23
Net margin-964.1%
FY ending Dec 2021: 20.2%20.2%FY ending Dec 2022: -126.6%-126.6%FY ending Dec 2023: -964.1%-964.1%FY21FY22FY23

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (4)
  • EDINET (FSA Japan)

    有価証券報告書-第16期(2025/01/01-2025/12/31)

    ID S100XV4M2026-03-27Open
  • EDINET (FSA Japan)

    有価証券報告書-第15期(2024/01/01-2024/12/31)

    ID S100VGO72025-03-26Open
  • EDINET (FSA Japan)

    有価証券報告書-第14期(2023/01/01-2023/12/31)

    ID S100T55F2024-03-27Open
  • EDINET (FSA Japan)

    有価証券報告書-第13期(2022/01/01-2022/12/31)

    ID S100QGWF2023-03-28Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.